Abrocitinib: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Abrocitinib appears in the FDA drug-label database. Marketed as CIBINQO.
- Drug class
- Janus Kinase Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Janus Kinase Inhibitors; P-Glycoprotein Inhibitors (as stated on the FDA label)
- Boxed warning
- The FDA label for Abrocitinib carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. ( 1 ) Limitation of Use : CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Phase breakdown
Conditions being studied
| Condition | Trials |
|---|---|
| Eczema · Abrocitinib for Eczema | 8 |
| Atopic Dermatitis · Abrocitinib for Atopic Dermatitis | 6 |
| Dermatitis, Atopic | 2 |
| Alopecia Areata | 1 |
| Atopic Dermatitis, Unspecified | 1 |
| Psoriasis | 1 |
Recruiting trials involving Abrocitinib
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
- A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
- A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
- Molecular Signatures in Inflammatory Skin Disease
- Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Common questions
Is Abrocitinib FDA-approved?
Yes, marketed as CIBINQO. Its FDA label carries a boxed warning.
How many recruiting trials involve Abrocitinib?
8 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.